Neuland Laboratories reports robust Q2 FY26 results: Net Profit up over 2.9x, Total Income surges
Neuland Laboratories announced strong Q2 FY26 financial results with significant increases in total income and net profit after tax for both consolidated and standalone figures.
The significant increase in revenue and profitability directly impacts the company's financial health and market valuation, suggesting a strong operational period.
The company reported substantial year-over-year growth in both total income and net profit after tax for the quarter and half-year ended September 30, 2025, indicating strong financial performance.
Neuland Laboratories Limited has published newspaper advertisements regarding its unaudited financial results for the quarter and half year ended September 30, 2025. The results were published in Financial Express and Nava Telangana on November 8, 2025. Key highlights of the financial performance include: * Consolidated Total Income for the quarter ended September 30, 2025, was ₹51,607.28 lakh, significantly up from ₹31,517.62 lakh in the corresponding quarter of the previous year. * Consolidated Net Profit after tax for the quarter was ₹9,685.39 lakh, a substantial increase from ₹3,284.27 lakh in the same period last year. * Consolidated Basic and Diluted Earnings Per Share (EPS) for the quarter stood at ₹75.49, compared to ₹25.60 in the prior year's quarter. * Standalone Total Income for the quarter ended September 30, 2025, was ₹51,607.18 lakh, up from ₹31,517.61 lakh in the corresponding quarter of the previous year. * Standalone Net Profit after tax for the quarter was ₹9,645.88 lakh, an increase from ₹3,195.84 lakh in the same period last year. * Standalone Basic and Diluted EPS for the quarter was ₹75.49, compared to ₹25.60 in the prior year's quarter.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 7, 2025.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.